Customer Publication

Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation

Authors: Zhenzhen Guo, Luyao Sun, Haojie Xia, Shibin Tian, Mengyue Liu, Jiejie Hou, Jiahuan Li, Haihong Lin, Gangjun Du

Journal: Molecules (2022)

Research Areas: Leukemia

Cell Lines: HL-60 (acute myeloid leukemia cell line)

Summary: This study aims to observe the differentiating effect of shikonin on Wilms’ tumor 1 (WT1)-positive HL-60 cells and investigate the fate of the differentiated leukemia cells. WT1 overexpression unaffected cell viability but promoted resistance to H2O2-induced DNA injury and cell apoptosis. The binding of shikonin to the WT1 protein was confirmed by molecular docking and drug affinity reaction target stability (DARTS). Shikonin at the non-cytotoxic concentration could decrease the WT1 protein , simultaneously reduce the CD34 protein, and increase the CD11b protein in a dose-dependent manner in normal HL-60 cells but not in WT1-overexpressed HL-60 cells. Long-term treatment of Shikonin for HL-60 attenuated cell proliferation, prevented the cell cycle and promoted cell apoptosis. HoloMonitor M4 was used to monitor the cell morphological changes with shikonin treatment.

Keywords: HoloMonitor M4, cell morphology, shikonin, leukemia, wilms’ tumor gene 1 (wt1), cd34, cell differentiation

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2